An alternate domain, 4-1BB, has been proven to be superior to CD28 in certain in vivo studies that indicate CARs having CD137 have improved anti-leukemic efficacy and improved persistence in the primary human lymphoblastic leukemia xenograft model. This evidence concerns the gene TNFRSF9 and acute lymphoblastic leukemia.